Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver
Introduction. Patients with chronic liver disease (CLD) are more likely to have severe morbidity and fatality rate due to superimposed acute or chronic hepatitis B (HBV) infection. The literature has shown that hepatitis B vaccines are safe and effective in patients with CLD, but the data in cirrhos...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2013/196704 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567817241624576 |
|---|---|
| author | D. Ajith Roni Rama Mohan Pathapati A. Sathish Kumar Lalit Nihal K. Sridhar Sujith Tumkur Rajashekar |
| author_facet | D. Ajith Roni Rama Mohan Pathapati A. Sathish Kumar Lalit Nihal K. Sridhar Sujith Tumkur Rajashekar |
| author_sort | D. Ajith Roni |
| collection | DOAJ |
| description | Introduction. Patients with chronic liver disease (CLD) are more likely to have severe morbidity and fatality rate due to superimposed acute or chronic hepatitis B (HBV) infection. The literature has shown that hepatitis B vaccines are safe and effective in patients with CLD, but the data in cirrhosis liver is lacking. We assessed the safety and immunogenicity of HBV vaccine in patients with cirrhosis liver. Methods. CTP classes A and B CLD patients negative for hepatitis B surface antigen and antibody to hepatitis B core antigen were included. All patients received three doses of hepatitis B vaccine 20 mcg intramuscularly at 0, 30, and 60 days. Anti-HBs antibody was measured after 120 days. Results. 52 patients with mean age years were studied. Response rates in CTP classes A and B were 88% and 33.3%. We observed that the alcoholic chronic liver disease had less antibody response (44%) than other causes of chronic liver disease such as cryptogenic 69% and HCV 75%. Conclusions. Patients with cirrhosis liver will have low antibody hepatitis B titers compared to general population. As the age and liver disease progress, the response rate for hepatitis B vaccination will still remain to be weaker. |
| format | Article |
| id | doaj-art-a621655ab0094c23b1d981143897bb9c |
| institution | Kabale University |
| issn | 1687-8639 1687-8647 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Virology |
| spelling | doaj-art-a621655ab0094c23b1d981143897bb9c2025-02-03T01:00:34ZengWileyAdvances in Virology1687-86391687-86472013-01-01201310.1155/2013/196704196704Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of LiverD. Ajith Roni0Rama Mohan Pathapati1A. Sathish Kumar2Lalit Nihal3K. Sridhar4Sujith Tumkur Rajashekar5Medical Gastroenterology, Narayana Medical College Hospital, Nellore, Andhra Pradesh 524002, IndiaClinical Pharmacology, Narayana Medical College Hospital, Nellore, Andhra Pradesh 524002, IndiaMedical Gastroenterology, Narayana Medical College Hospital, Nellore, Andhra Pradesh 524002, IndiaMedical Gastroenterology, Narayana Medical College Hospital, Nellore, Andhra Pradesh 524002, IndiaMedical Gastroenterology, Narayana Medical College Hospital, Nellore, Andhra Pradesh 524002, IndiaClinical Pharmacology, Narayana Medical College Hospital, Nellore, Andhra Pradesh 524002, IndiaIntroduction. Patients with chronic liver disease (CLD) are more likely to have severe morbidity and fatality rate due to superimposed acute or chronic hepatitis B (HBV) infection. The literature has shown that hepatitis B vaccines are safe and effective in patients with CLD, but the data in cirrhosis liver is lacking. We assessed the safety and immunogenicity of HBV vaccine in patients with cirrhosis liver. Methods. CTP classes A and B CLD patients negative for hepatitis B surface antigen and antibody to hepatitis B core antigen were included. All patients received three doses of hepatitis B vaccine 20 mcg intramuscularly at 0, 30, and 60 days. Anti-HBs antibody was measured after 120 days. Results. 52 patients with mean age years were studied. Response rates in CTP classes A and B were 88% and 33.3%. We observed that the alcoholic chronic liver disease had less antibody response (44%) than other causes of chronic liver disease such as cryptogenic 69% and HCV 75%. Conclusions. Patients with cirrhosis liver will have low antibody hepatitis B titers compared to general population. As the age and liver disease progress, the response rate for hepatitis B vaccination will still remain to be weaker.http://dx.doi.org/10.1155/2013/196704 |
| spellingShingle | D. Ajith Roni Rama Mohan Pathapati A. Sathish Kumar Lalit Nihal K. Sridhar Sujith Tumkur Rajashekar Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver Advances in Virology |
| title | Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver |
| title_full | Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver |
| title_fullStr | Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver |
| title_full_unstemmed | Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver |
| title_short | Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver |
| title_sort | safety and efficacy of hepatitis b vaccination in cirrhosis of liver |
| url | http://dx.doi.org/10.1155/2013/196704 |
| work_keys_str_mv | AT dajithroni safetyandefficacyofhepatitisbvaccinationincirrhosisofliver AT ramamohanpathapati safetyandefficacyofhepatitisbvaccinationincirrhosisofliver AT asathishkumar safetyandefficacyofhepatitisbvaccinationincirrhosisofliver AT lalitnihal safetyandefficacyofhepatitisbvaccinationincirrhosisofliver AT ksridhar safetyandefficacyofhepatitisbvaccinationincirrhosisofliver AT sujithtumkurrajashekar safetyandefficacyofhepatitisbvaccinationincirrhosisofliver |